Group 1 - The core viewpoint of the article highlights that Jinbo Bio achieved significant growth in both revenue and net profit in the first half of 2025, with a net profit of 392 million yuan, representing a year-on-year increase of 26.65% [1][2] - The company's revenue reached 859 million yuan, marking a 42.43% increase compared to the same period last year, with a basic earnings per share of 3.41 yuan [2][3] - The medical device segment showed strong performance, generating 708 million yuan in revenue, accounting for over 80% of total sales, with a gross margin of 95.04% [3][4] Group 2 - Jinbo Bio's gross margin decreased to 90.68%, down 0.90 percentage points year-on-year, while the net profit margin fell to 45.50%, a decline of 5.84 percentage points [5] - The company reported a net cash flow from operating activities of 383 million yuan, with cash received from sales amounting to 882 million yuan [6] - Jinbo Bio plans to distribute a cash dividend of 10 yuan per 10 shares to all shareholders, totaling approximately 115 million yuan [7] Group 3 - The company significantly increased its R&D expenses by 85.43% to 45.8 million yuan, alongside a 67.77% rise in sales expenses, indicating a strong commitment to technological investment and market expansion [7] - The investment landscape in the beauty industry shows heightened activity, particularly in the recombinant collagen sector, with Jinbo Bio being a key player [10][11] - As of August 11, Jinbo Bio's stock price reached 320 yuan per share, with a total market capitalization of 36.8 billion yuan, reflecting a year-to-date increase of over 101% [12]

Core Viewpoint - Jinbo Bio achieved significant growth in both revenue and net profit in the first half of 2025, with a notable increase in R&D expenses, indicating a strong focus on innovation and market expansion [2][9]. Financial Performance - The company reported a revenue of 859 million yuan, representing a year-on-year increase of 42.43% [5][6]. - Net profit reached 392 million yuan, up 26.65% compared to the previous year [5][6]. - Basic earnings per share were 3.41 yuan, reflecting a 26.77% increase [6]. Profitability Analysis - The gross profit margin was 90.68%, down 0.90 percentage points year-on-year [7]. - The net profit margin decreased by 5.84 percentage points to 45.50% [7]. - The medical device segment generated 708 million yuan in revenue, accounting for over 80% of total sales, with a high gross margin of 95.04% [7]. Cash Flow and Dividends - The net cash flow from operating activities was 383 million yuan, with cash received from sales amounting to 882 million yuan [8]. - The company announced a cash dividend of 10 yuan per 10 shares, totaling approximately 115 million yuan [9]. R&D and Market Strategy - R&D expenses surged by 85.43% to 45.8 million yuan, while sales expenses increased by 67.77% [9]. - The growth in the medical device sector was primarily driven by the sales of implant products based on recombinant human collagen [7]. Industry Context - The investment landscape in the beauty and cosmetic raw materials sector is highly active, particularly in the recombinant collagen segment, which has seen significant financing activities [13][14]. - Jinbo Bio's strategic partnership with Yangshengtang, which invested 3.4 billion yuan for a 10.58% stake, is expected to enhance its market penetration and operational efficiency [12]. Market Performance - As of August 11, Jinbo Bio's stock price was 320 yuan per share, with a total market capitalization of 36.8 billion yuan, reflecting a year-to-date increase of over 101% [15].

Investment Rating - The report maintains a "Buy" rating for the cosmetics and medical beauty sector, particularly highlighting companies like Shiseido and Up Beauty for their strong performance and growth potential [12][14]. Core Insights - The cosmetics and medical beauty sector underperformed the market during the week of August 1 to August 8, 2025, with the Shenwan Beauty Care Index growing by 1.7%, which is lower than the overall market performance [5][6]. - There is a notable divergence in the performance of domestic beauty brands in July, with strong growth observed in skincare brands like Han Shu and Marubi, while color cosmetics lagged due to weather and promotional timing [11][12]. - Up Beauty's H1 2025 performance exceeded expectations, with revenue projected between 4.09 to 4.11 billion yuan, reflecting a year-on-year growth of 16.8% to 17.3% [12][13]. Summary by Sections Industry Performance - The Shenwan Cosmetics Index increased by 1.3%, underperforming the Shenwan A Index by 0.6 percentage points, while the Shenwan Personal Care Index rose by 4.2%, outperforming the Shenwan A Index by 2.3 percentage points [5][6]. - The top-performing stocks in the sector included Up Beauty (+18.4%), Reliable Shares (+13.7%), and Lafang Home (+11.3%) [7]. Key Company Updates - Up Beauty's H1 2025 earnings report indicated a significant profit increase, with net profit margins improving due to optimized channel structures and a higher proportion of high-margin brands [12][13]. - Shiseido reported a 7.6% decline in sales for H1 2025, marking the largest drop in five years, with a notable decrease in the Chinese market [24]. E-commerce Insights - In July 2025, domestic beauty brands showed varied performance on major e-commerce platforms, with Han Shu achieving a 58% increase in GMV on Douyin, while color cosmetics faced challenges [20][21]. - The overall retail sales of cosmetics in June 2025 saw a decline of 2.3%, attributed to the pre-promotion of the 618 shopping festival [21][24]. Market Trends - The report highlights a shift in market dynamics, with domestic brands gaining market share against international competitors, particularly in the skincare segment [34][35]. - The Chinese skincare market is projected to reach 271.2 billion yuan in 2024, despite a 3.7% decline in growth [34][35].

Core Viewpoint - Huaxi Bio, once a star in the medical beauty sector, has seen a significant decline in stock price and market value since its peak in 2021, prompting the controlling shareholder to announce a share buyback plan for the first time since its IPO in 2019 [3][5][7]. Group 1: Stock Performance and Market Sentiment - Huaxi Bio's stock price peaked at approximately 312.99 yuan, but has since dropped about 82%, with a market value evaporating over 100 billion yuan [3][5]. - The controlling shareholder plans to buy back shares worth 200 million to 300 million yuan, with a maximum purchase price of 70 yuan per share, which is relatively small compared to the current market value of 25.3 billion yuan [5][7]. - Following the announcement, the stock experienced a brief increase of about 3% but closed with only a 0.71% gain, indicating limited market impact [7]. Group 2: Institutional Investor Behavior - Institutional funds have been steadily exiting Huaxi Bio, with the number of funds holding shares dropping from 421 at the end of 2022 to 158 by the end of 2024, and the total shareholding value decreasing significantly [10][12]. - The Hong Kong Central Clearing and Settlement System also reported a reduction in holdings, with shares decreasing from 816.1 million to 448.7 million over six months [12]. - The second-largest shareholder, a private equity fund under China Life, has also been reducing its stake, indicating a broader trend of capital flight from the company [12][16]. Group 3: Financial Performance and Strategic Challenges - Huaxi Bio's revenue and profit growth has sharply declined, with 2023 showing a revenue drop of 4.45% and a net profit decrease of 38.97%, followed by an even worse performance in 2024 [20][22]. - The company's strategic shift towards consumer products has not yielded the expected results, leading to increased marketing expenses and a decline in overall profitability [25][26]. - The competitive landscape has intensified, with rivals gaining market share in both B-end and C-end markets, eroding Huaxi Bio's previous advantages [26][27]. Group 4: Management Issues and Allegations - Frequent changes in the management team have raised concerns about internal stability, with ten executive changes reported in 2024 alone [29]. - Allegations of financial misconduct have surfaced, with a former executive claiming to have evidence of financial fraud, although the company has denied these claims [33][35]. - Previous reports of shareholder grievances regarding the treatment of employee stock options have also surfaced, further complicating the company's reputation [35].

Group 1: Collagen Industry Insights - Collagen is a vital component in the human body, providing strength, flexibility, and structural support to various tissues, including skin and bones [5][6] - The domestic recombinant collagen market is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, surpassing the growth rate of animal-derived collagen at 27.7% [6][7] - The application of recombinant collagen spans various sectors, including aesthetic medicine, skincare, intimate health, and hair health, with significant market growth anticipated in each area [7][8] Group 2: Investment Recommendations - The report suggests focusing on companies like Jinbo Biological, which leads in recombinant collagen medical products, and Juzi Biological, known for its strong presence in the beauty market [8] - The domestic beauty care market is rapidly evolving, with increasing consumer acceptance of new products and a growing focus on efficacy and core ingredients [8] Group 3: Changan Automobile Company Overview - Changan Automobile reported a wholesale sales volume of 210,600 vehicles in July 2025, reflecting a year-on-year increase of 23.43% [11][12] - The establishment of the China Changan Automobile Group aims to enhance the integration of the industry chain and promote the development of new energy vehicles [13] - The company plans to launch over 50 global new energy products in the next five years, indicating a strong commitment to innovation and market expansion [13][14]

Investment Rating - The report suggests a focus on companies in the recombinant collagen sector, highlighting their potential for growth and market leadership [5][6]. Core Insights - Collagen is essential for human health, providing structural support and biological functions [11][14]. - The domestic recombinant collagen technology is advanced, with a complete industrial chain and supportive policies driving growth [6][31]. - The market for recombinant collagen is expected to grow significantly, with a projected CAGR of 41.4% from 2023 to 2027, surpassing the growth of animal-derived collagen [6][27]. - The applications of collagen are diverse, including medical aesthetics, skincare, intimate health, and hair health [6][33]. Summary by Sections 1. Collagen as a Vital Component - Collagen constitutes 30%-40% of human protein and is crucial for skin, bones, tendons, and ligaments [11][14]. - There are at least 29 types of collagen in the human body, with types I and III being the most common in the skin [14][15]. 2. Production: Recombinant vs. Animal-Derived Collagen - Recombinant collagen is produced using gene engineering, offering advantages such as no virus risk and better biocompatibility compared to animal-derived collagen [19][26]. - The market for recombinant collagen is expected to reach 286.3 billion yuan in 2023, with a significant growth trajectory [27][28]. 3. Policy Support for Market Development - The regulatory framework for recombinant collagen has been improving, with various guidelines issued since 2021 to standardize the industry [31][32]. 4. Diverse Applications of Recombinant Collagen - **Medical Aesthetics**: The market for recombinant collagen in medical aesthetics is projected to grow from 43 billion yuan in 2023 to 143 billion yuan by 2027, with a CAGR of 35.4% [6][42]. - **Skincare**: The market for functional skincare products containing recombinant collagen is expected to grow from 115 billion yuan in 2023 to 665 billion yuan by 2027, with a CAGR of 54.9% [47][49]. - **Intimate Health**: The market for intimate health products is anticipated to grow significantly, driven by increasing consumer awareness and demand [51][52]. 5. Key Companies in the Industry - **Jinbo Biological**: A leader in recombinant collagen with unique medical aesthetic products [5][40]. - **Juzi Biological**: Known for its brands Kefu Mei and Keli Jin, actively expanding its medical aesthetic pipeline [5][40]. - **Marubi Biological**: Accelerating its research in collagen, with significant product launches [5][40].

Group 1 - The stock price of Marubi Biotechnology closed at 40.04 yuan on July 30, 2025, down 0.15% from the previous trading day, with a trading volume of 0.87 billion yuan and a turnover rate of 0.54% [1] - Marubi Biotechnology operates in the beauty care industry, focusing on anti-aging eye products, with main brands "Marubi" and makeup brand "PL Love Fire" [1] - The company is transitioning towards the biotechnology sector by restructuring its collagen research and plans to expand into the medical beauty and healthcare industries [1] Group 2 - Marubi Biotechnology has commenced construction of a Class III medical device pilot base in Zhuhai International Health Port, focusing on the research and industrialization of recombinant collagen [1] - The company has set a ten-year research plan aiming to obtain a registration certificate for injectable recombinant collagen Class III medical devices by 2026 [1] - In 2024, the company plans to invest 73.54 million yuan in research and development, employing 94 research personnel [1] Group 3 - On July 30, 2025, the net outflow of main funds for Marubi Biotechnology was 12.24 million yuan, accounting for 0.08% of the circulating market value [2]

Core Viewpoint - Marubi Biological has officially started construction on a Class III medical device pilot base in Zhuhai, focusing on the research and industrialization of recombinant collagen protein in the medical beauty field, indicating a strategic shift from a cosmetics company to a biotechnology company [1][3]. Company Developments - The project aims to deepen research into recombinant collagen protein, expanding its application from cosmetic beauty to medical beauty, reflecting Marubi's ambition to enhance its competitive edge in the cosmetics industry and explore new revenue streams in the medical sector [1][3]. - Marubi has changed its name from "Marubi Co., Ltd." to "Marubi Biological" and has invested in medical biomaterials companies, signaling a commitment to this new direction [1][3]. Market Trends - The focus on recombinant collagen protein aligns with Marubi's historical emphasis on anti-aging products, particularly in eye care, and the growing popularity of this ingredient in the skincare market [3][4]. - The market for recombinant collagen protein is still in its early stages, presenting opportunities for early entrants like Marubi to capture market share [3][4]. Research and Development Strategy - Marubi plans to invest over 1 billion yuan in recombinant collagen protein research by 2032, with specific milestones including obtaining medical device registration by 2026 and advancing into serious medical applications by 2028 [4][5]. - Despite the ambitious R&D plans, Marubi's R&D expenses have not kept pace with revenue growth, leading to a decline in R&D expense ratios from 2.80% in 2023 to 2.48% in 2024 [5][9]. Financial Performance - Marubi's revenue has shown significant growth, surpassing 2.2 billion yuan in 2023, a 28.52% increase from the previous year, with projections indicating potential revenue exceeding 3 billion yuan by 2025 [7][9]. - The company has successfully adapted its marketing strategies, particularly through online channels and product focus, contributing to its revenue growth [7][8]. Competitive Landscape - Marubi faces challenges from increasing online marketing costs and rising sales expenses, which have impacted profitability, with net profit margins decreasing from 26.56% in 2020 to 11.52% in 2024 [9][10]. - The reliance on a single ingredient, recombinant collagen protein, poses risks, as market trends can shift rapidly, potentially affecting long-term sustainability [9][10].

胶原蛋白赛道或将迎来竞争高峰期。 药企德展健康日前宣布，其重组Ⅲ型及XVII型人源化胶原蛋白已实现中试生产，并具备化妆品原料销 售能力。但在这项技术突破背后，横亘着医药级原料转化的巨大鸿沟——规模化生产线仍在建设中，真 正的产业化部署尚未完成。 事实上，在所有玩家头顶高悬的双重高压线并未松动：技术层面，医美级产品的规模化生产与质量控制 仍如绝壁矗立；准入层面，长达36个月的三类医疗器械审批周期与超千万元的单产品合规成本构筑着钢 铁闸门。 围绕重组胶原蛋白项目技术突破及申报节奏，21世纪经济报道以投资者身份致电德展健康。该公司工作 人员回复道："其技术路线与巨子生物等行业头部企业同属人源化胶原蛋白范畴，并无本质差别。当前 中试生产规模维持在500L水平，产品技术性能可满足护肤品、医美等商业化应用需求。" 但工作人员同时指出，由于尚未建立规模化量产能力，具体产业化路径仍需结合后续产能建设情况确 定。 德展健康产品结构显示，公司已布局重组胶原蛋白原料及其衍生产品体系。2024年，重组Ⅲ型人源化胶 原蛋白不仅实现原料销售，其创新的冻干海绵剂型产品也通过备案审批。 作为第三代胶原蛋白技术，该产品通过DNA重组技术构建三 ...

Investment Rating - The report initiates coverage with an OUTPERFORM rating, setting a target price of Rmb 419.80, indicating a potential upside of 25.5% from the current price of Rmb 338.65 [2][9]. Core Insights - Shanxi Jinbo Bio-Pharmaceutical is a leading domestic company in the industrialization of recombinant human collagen, holding three Class III medical device certificates for its products, which positions it favorably in the market [3][11]. - The company reported a revenue of Rmb 1.44 billion in 2024, reflecting a year-on-year growth of 84.92%, driven by significant increases in its medical devices, functional skincare products, and raw materials segments [3][8]. - The report anticipates revenue growth for 2025-2027 to reach Rmb 2.17 billion, Rmb 2.92 billion, and Rmb 3.72 billion, respectively, with growth rates of 55%, 37%, and 29% [9]. Summary by Sections Company Overview - Shanxi Jinbo Bio-Pharmaceutical specializes in recombinant collagen medical devices, with a focus on injectable products that are classified as Class III medical devices, which have stringent approval processes and high technical barriers [3][11]. - The company has established a significant market presence with its proprietary brand Wei Yimei and has also engaged in contract manufacturing for L'Oréal's SkinCeuticals brand [3][27]. Financial Performance - The company has shown consistent revenue and profit growth over the past five years, with a net profit of Rmb 732 million in 2024, up 144% year-on-year [8][9]. - The gross profit margin for 2024 was reported at 92.02%, with the medical device segment achieving a margin of 95.03% [8][9]. Product and Market Position - The medical device segment accounted for 87% of total revenue in 2024, with a compound annual growth rate (CAGR) of 94% from 2020 to 2024 [25][27]. - Jinbo Bio's main products include recombinant collagen injectables, which are primarily used in aesthetic medicine and surgical repair treatments [23][27]. Strategic Partnerships - The company has formed a strategic partnership with Yangshengtang, leveraging its extensive retail network of over 3 million outlets to enhance market penetration and brand visibility [4][20]. - This collaboration is expected to facilitate the application of Jinbo's collagen products across various sectors, including skincare and health products [4][20]. Research and Development - Jinbo Bio is actively investing in R&D, with a focus on its new drug EK1, which is in the pre-clinical stage and aims to address broad-spectrum antiviral needs [5][9]. - The company holds multiple patents for its core ingredients, enhancing its competitive edge in the high-end skincare market [4][20].